Phase 4 Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 20 years or older
- People who have been diagnosed with moderate or severe reduced blood flow in the lower legs and also have a wound on a lower limb
- People whose doctors have determined, after vascular examination and CT imaging, that no further procedures (such as balloon angioplasty) are possible to improve blood flow
- People whose wound measures at least 1×1 cm and no larger than 3×3 cm
- People who are able to follow the trial schedule and attend all required visits
- People who have read and fully understood the trial information and have given written agreement to participate
Who may not be able to join:
- People with conditions that affect nerve or muscle function, such as myasthenia gravis, Eaton-Lambert syndrome, ALS (motor neurone disease), or motor neuropathy
- People who have taken certain antibiotics (aminoglycosides, tetracyclines, lincomycin-type) or medications that affect muscle or nerve function (such as muscle relaxants, anticholinergics, benzodiazepines, or similar drugs) within 4 weeks before screening
- People who have taken aspirin, anti-inflammatory pain medications (NSAIDs), or blood thinners within 7 days before screening
- People who have received any botulinum toxin treatment within 3 months before screening
- People where imaging shows that one or more of the three main blood vessels in the lower leg remains open (confirm with trial site)
- People where doctors determine that balloon angioplasty could restore blood flow to the lower leg, even if all three main vessels are blocked
- People currently taking, or who have taken within one month of screening, steroids or immune-suppressing medications that may affect wound healing
- People who have used injectable medications or wound-covering products intended to help wound healing within 1 week before screening
- People who are pregnant, breastfeeding, planning to become pregnant during the trial period, or women of childbearing age who are not using an available form of contraception
- People with a known allergy or sensitivity to botulinum toxin
- People who have participated in another clinical trial within 30 days before screening, or where the investigational product from a previous trial has not yet fully cleared the body — whichever period is longer
- People whom the trial investigators determine are otherwise unsuitable for participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hiisun J, Dr, Yonsei University College of Medicine, Yongin Severance
Phone: 823151899730
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in tcPO2(mmHg) measurement within the edge of 1cm Diabetic foot wound at 7 days and 14 days after IP compared to baseline(Pre-administration IP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.